ACVR1-driven glycolysis promotes lactate-dependent H3K18la that activates neuronal NLRP3 pyroptosis to sustain neuropathic pain. Pharmacological blockade of ACVR1 or lactylation reverses established pain, positioning this immunometabolic axis as a tractable therapeutic target.
Zhao et al. (2026) studied this question.